ArticlePloS one2026
Maternal outcomes at mid-altitudes in anemic pregnant women: Evidence from the WOMAN-2 trial.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundHigh residential altitude is associated with adverse pregnancy outcomes, yet most research has focused on elevations above 2500 meters. There is limited evidence on how altitude impacts maternal health below this threshold, where 99% of the global population resides. We investigated the effect of mid-altitudes on maternal outcomes among women with moderate to severe anemia who delivered in hospitals in four sub-Saharan and Asian countries.
methodsWe analysed data from the World Maternal Antifibrinolytic-2 (WOMAN-2) trial, which recruited anaemic women admitted for vaginal delivery across 42 hospital sites in Nigeria, Pakistan, Tanzania, and Zambia. We compared women in mid-altitudes (1,000-2,499 m) with those at low-altitudes (< 1,000 m) using postpartum blood loss as the primary outcome. The key secondary outcome was clinical postpartum haemorrhage (PPH). Additional secondary outcomes included prenatal maternal health indicators (gestational age at labor onset, hypertensive disorders of pregnancy, baseline hemoglobin, severe anemia, and mean arterial pressure [MAP]), as well as intrapartum intervention indicators (assisted delivery, use of medical pain control, and use of oxytocin in labor). We used STATA version 18 for data analysis. We used classical logistic and modified Poisson regressions with cluster-robust standard errors to estimate the odds and risk ratios (RR) for dichotomous outcomes and linear regression with cluster-robust variance to estimate the β coefficients for the continuous outcomes.
resultsOf 15,068 women, 4801 (31.9%) delivered at mid-altitude and 10,267 (68.1%) at low-altitudes. Delivery in mid-altitudes did not independently affect postpartum blood loss (β = 37.89 mL; 95% CI: -26.83-102.62), p = 0.243. Mid-altitude delivery compared to low-altitude was independently associated with a 22% lower risk of preterm delivery (aRR = 0.78; 95%CI: 0.73-0.83), p < 0.001, and a 26% lower risk of severe anaemia (aRR = 0.74; 95% CI: 0.68-0.82), p < 0.001. The use of medical pain control was 2.2 times higher (aRR = 2.20; 95% CI: 2.02-2.40), p < 0.001, and the Odds of assisted delivery were 46% more likely (aOR = 1.46; 95% CI: 1.20-1.78) at mid-altitudes compared to low-altitudes.
conclusionDelivery at mid-altitudes was not independently associated with postpartum blood loss, but generally exhibited more favorable prenatal maternal health indicators and more intrapartum interventions than those delivering at low-altitudes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.